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Abstract 22 
 23 
Background. Plasmodium vivax recurrences help maintain malaria transmission. They are 24 
caused by recrudescence, reinfection or relapse, which are not easily differentiated.  25 
Methods. A longitudinal observational study took place in Turbo municipality, Colombia. 26 
Participants with uncomplicated P. vivax infection received supervised concomitantly 27 
treatment with chloroquine 25 mg/Kg and primaquine 0.25 mg/Kg/day for 14 days. Incidence 28 
of recurrence was assessed over 180 days. Samples were genotyped and origins of 29 
recurrences were established. 30 
Results. 134 participants were enrolled between February 2012 and July 2013, and 87 were 31 
followed for 180 days in which 29 recurrences were detected. Cumulative incidence of first 32 
recurrence was 24.1% (21/87) (CI 95% 14.6 to 33.7) and 86% (18/21) of them occurred 33 
between days 51 and 110. High genetic diversity of P. vivax was found and 12.5% (16/128) 34 
of the infections were polyclonal. Among detected recurrences 93.1% were genotyped as 35 
genetically identical to the one from the previous episode and 65.5% (19/29) were classified 36 
as relapses. 37 
Conclusion. Our results indicate that there is a high incidence of P. vivax malaria recurrence 38 
after treatment in Turbo municipality, Colombia, a large majority of which are likely relapses 39 
from the previous infection. We attribute this to the primaquine regimen currently used in 40 
Colombia, which may be insufficient to eliminate hypnozoites.  41 
 42 
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Background  44 
 45 
Plasmodium vivax has the widest global distribution of the human malaria parasites (1, 2). In 46 
the Americas, more than 60% of the annual cases of malaria are caused by P. vivax (2). This 47 
parasite has a dormant stage known as hypnozoite, in which it remains in the liver for an 48 
indeterminate length of time (3). Hypnozoites might be activated months after a previous 49 
episode that has been treated and cured, causing relapses (3). Relapses after treatment can 50 
cause a new clinical episode with risk of complications for the patient. Moreover, they may 51 
contribute to continue P. vivax transmission (4, 5). 52 
  53 
In endemic areas, recurrent P. vivax infections have three origins: 1) recrudescence of 54 
parasites from blood, which could be caused by resistance to treatment, inadequate dosage 55 
or suboptimal drug absorption, 2) reinfection by inoculation of new parasites from mosquito 56 
bites, or 3) relapse by reactivation of hypnozoites from the liver (6). Diagnostic methods 57 
alone cannot distinguish among these three types of recurrence. However, a comprehensive 58 
study — including supervised treatment, individual follow-up for therapeutic efficacy, 59 
microscopic and molecular diagnosis, quantification of drugs in blood, and genetic 60 
characterization of the parasites — may allow to determine the source of the recurrence (7, 61 
8).  62 
 63 
Per current recommendations of the World Health Organization, the treatment for P. vivax 64 
infection consists of two drugs: chloroquine (CQ), a blood schizonticide against circulating 65 
parasites, and primaquine (PQ), a tissue schizontocide that clears the liver of schizonts (9). 66 
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CQ remains widely used against P. vivax, although treatment failures have been reported 67 
(10). In Colombia, to this date there have been no reports of CQ therapeutic failure for P. 68 
vivax (11). PQ is the only antimalarial commercially available to treat liver stages (12).  69 
 70 
Previous studies have compared the efficacy of different PQ regimens in preventing P. vivax 71 
recurrence (13). Although the standard PQ regimen (0.25 mg/kg/day for 14 days) has a 72 
significant incidence of recurrence, it is the most commonly used worldwide (2). It was 73 
estimated that 16.2% of patients in Colombia, treated with this regimen have at least one 74 
recurrence within six months (14). Nevertheless, the standard PQ regimen yield a lower 75 
incidence of recurrences compared to regimens employing an equal total dose administered 76 
for a shorter time (13, 14).  77 
 78 
We conducted a prospective study in an endemic region of Colombia, to determine the 79 
incidence of P. vivax recurrences in a six month period post-treatment in patients underwent 80 
a supervised CQ-PQ regimen. Associations between risk factors and recurrence were 81 
explored, and P. vivax parasites from all episodes were genotyped in order to distinguish 82 
between relapses and reinfections. 83 
 84 
Materials and methods 85 
 86 
Study site 87 
This study was conducted in Turbo municipality, Antioquia department, located in northwest 88 
Colombia (8°5´42´´N, 76°44´123´´W) (Figure1). Turbo has an area of 3,055 km² and 89 
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approximately 135,967 inhabitants, 61% of whom live in the rural area. The main economic 90 
activity is banana and plantain cultivation. Malaria is endemic in Turbo, with peaks of highest 91 
transmission between February and June, according to recent statistics 80% of malaria cases 92 
in the area are P. vivax mono-infections (15). Over the past seven years the number of cases 93 
has been reduced significantly, from an annual parasite incidence (API) of 65 cases per 1,000 94 
people in 2007 to 3 cases per 1,000 people in 2014 (15).  95 
 96 
Study design  97 
A longitudinal observational study was conducted. Participants were selected from four 98 
malaria diagnostic centers (the municipal hospital and three nearby health centers) between 99 
February 2012 and July 2013 (Figure 1). These centers account for about 20% of all P. vivax 100 
reported cases in the Turbo municipality. 101 
 102 
All individuals diagnosed with P. vivax malaria in the diagnostic centers during the study 103 
period were invited to participate. Eligibility criteria were: mono-infection with P. vivax, 104 
asexual parasite count greater than 250 parasites/µl, age over 4 years, absence of general 105 
danger signs or signs of severe malaria according to the criteria adopted by World Health 106 
Organization (7, 9), negative pregnancy test, not breastfeeding, not reporting intake of 107 
antimalarials in the preceding four weeks, residence in the study area and the ability and 108 
willingness to comply with the protocol for the duration of the study. 109 
 110 
Participants received supervised simultaneous treatment with CQ (25 mg/kg for 3 days) and 111 
PQ (0.25 mg/kg/day for 14 days) (16). Patients weighing 60 kg or over received the 112 
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maximum dose of CQ (1.5 g), while the PQ dose was adjusted for body weight. Information 113 
about demographic characteristics, current disease, history of malaria, travel to other endemic 114 
regions and use of preventive measures for malaria was collected. Participants were 115 
monitored by thick blood smears and surveillance for symptoms on days 1, 2, 3, 7, 13, 21 116 
and 28 post-diagnosis to evaluate therapeutic response during the current episode (7). The 117 
evaluation for recurrences was carried out by monthly thick blood smear on days 60, 90, 120, 118 
150, 180 and at any time the patient had symptoms consistent with malaria.  119 
 120 
Recurrence was defined as a positive thick blood smear for P. vivax between days 29 and 121 
180, with or without clinical symptoms. In all recurrences, participants were treated again 122 
with the same CQ-PQ regimen, and they continued the follow-up as scheduled until day 180.  123 
 124 
For patients who did not meet one or more inclusion criteria, a sample of capillary blood was 125 
taken before treatment but no study treatment or follow-up was provided. These samples 126 
were used for malaria diagnosis and parasite genotyping; results provided information for 127 
baseline parasite genetic diversity in the study area.  128 
 129 
All participants enrolled signed an informed consent. This study was approved by the ethics 130 
committee from School of Medicine of the University of Antioquia, Colombia. The 131 
investigators from the Centers for Disease Control and Prevention (CDC) did not engage in 132 
field study or have access to participants’ personal identifying information. Therefore, their 133 
participation in this study was determined to be non-engaged after human subject review at 134 
CDC.   135 
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 136 
Malaria diagnosis and genetic characterization 137 
Malaria diagnosis on the day of inclusion (considered Day Zero) and on each scheduled visit 138 
was carried out by microscopy (17). Diagnosis was confirmed by PCR on days 0, 28 and the 139 
day of recurrence. DNA samples were extracted from filter paper with blood spots by 140 
saponin-chelex method (18) and they were analyzed using a nested PCR protocol described 141 
by Snounou et al (19). 142 
 143 
All samples determined to be P. vivax mono-infection by PCR were genotyped at seven 144 
neutral microsatellite loci (MS) (20, 21). Microsatellites MS2 (chromosome 6), MS6 145 
(chromosome 11) and MS20 (chromosome 10), previously described by Karunaweera et al., 146 
were amplified by simple PCR (21), while microsatellites 2.21 (chromosome 2) 3.502 147 
(chromosome 3), 11.162 (chromosome 11) and 12.335 (chromosome 12), described by 148 
Imwong et al., were amplified by semi-nested PCR (20). For each MS amplification, a 149 
forward primer labeled with a fluorophore (FAM or HEX) was used. PCR products were 150 
analyzed by capillary electrophoresis on an ABI Prism 3130xl sequencer (Applied 151 
Biosystems) using ROX 350 (Applied Biosystems) as an internal standard. Fragment size 152 
and allele determination were obtained using Genemapper v4.1 (7 (Applied Biosystems, 153 
Foster City, CA). Samples for which some loci did not amplify were re-amplified twice. If 154 
two or more alleles were amplified in a single locus of a given sample, and the signal from 155 
the minor allele was greater than 33% of that of the predominant signal allele, the sample 156 
was defined as being polyclonally infected (22). 157 
 158 
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Data analysis 159 
 160 
Incidence of recurrences and risk factors 161 
The information was reviewed in the field and validated for quality control, then entered into 162 
a database. Cumulative incidence of first recurrence was calculated using Kaplan-Meier 163 
survival analysis. Association of potential risk factors with recurrence was analyzed using 164 
Cox proportional hazards model with the extension proposed by Andersen & Gill, which 165 
allows multiple events per participant (23). Crude and adjusted hazard ratios (HR) and their 166 
95% confidence intervals (CI 95%) were calculated. Selection of variables for calculating 167 
adjusted HR was made by biological plausibility and according to P value <0.25 in bivariate 168 
analysis (24). For quantitative variables, linear assumption of risk was evaluated, and if it 169 
was not met, the variables were dichotomized at the median or previously reported thresholds 170 
(25, 26). All analyses were carried out using Stata 11.2 software (StataCorp, College Station, 171 
TX). 172 
 173 
Genetic diversity and genetic structure 174 
For samples with monoclonal infection, the total number of alleles per locus and expected 175 
heterozygosity (He) was estimated. He represents the probability of finding two different 176 
alleles for a given locus on a pair of randomly selected samples from the study population 177 
(27). Additionally, the number of multilocus haplotypes (MLH) was estimated, defined as a 178 
unique combination of alleles for the 7 MS analyzed. These analyzes were conducted with 179 
GenAlEx (28) and Microsatellite toolkit applications from Microsoft Excel (29). The 180 
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percentage of polyclonal infection per locus and average number of alleles per locus was 181 
calculated for all samples on Day Zero and day of recurrence.  182 
 183 
Given that unknown population substructures could bias our observations, we explored 184 
whether the sampled parasites could be considered as one population undergoing random 185 
matting. In particular, the parasite population structure was evaluated in Structure v2.3.4, 186 
which uses a Bayesian clustering approach to assign samples to one of K genetic groups 187 
according to allele frequency per locus; the data were evaluated using values of K from 2 to 188 
10. For each value of K, 10 independent runs were performed, with a burn-in period of 10,000 189 
iterations followed by 100,000 iterations (30). Structure Harvester v0.6.94 program was used 190 
to visualize the Structure output results (31). The most likely number of genetic groups within 191 
the sample was found according to the method of Evanno et al. 2005 (32). These analyses 192 
were complemented by inferring the MLH genealogies using the Global Optimal eBURST 193 
algorithm (33), as implemented in PHYLOViZ (34). Using an extension of the goeBURST 194 
rules up to n locus variants level (nLV, where n equals to the number of loci in our dataset: 195 
seven), a Minimum Spanning Tree-like structure was drawn to cluster the MLH into a clonal 196 
complex based on their multilocus genotypes. 197 
 198 
Classification of recurrences 199 
The multilocus genotype of the samples from Day Zero and the recurrence day in participants 200 
with recurrence were compared. If both samples had exactly the same allele at each locus for 201 
all 7 MS analyzed, i.e identical MLH, it was considered an identical recurrence. In case of a 202 
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polyclonal infection on Day Zero, the recurrence was considered to be from the same MLH 203 
when all alleles for 7 MS analyzed in the recurrence day were present on Day Zero. 204 
 205 
For participants with identical haplotypes at zero and recurrence days, the probability that a 206 
second infection with same haplotype occurred by chance was estimated as the P(match) 207 
considering the relative frequency of each MLH in the day-zero population (35-37).  The 208 
P(match) was estimated by multiplying each MLH relative frequency within each of the two 209 
genetic clusters (i.e. subpopulations) obtained by Bayesian analysis in the Day Zero sample 210 
set, by their relative frequency in the recurrence population. Polyclonal infections were 211 
excluded for this analysis, except samples from participants with a recurrence in which the 212 
haplotype frequency from the recurrence day was considered. When P(match) was <0.05, the 213 
recurrence was classified as a relapse, otherwise it was considered a reinfection by the same 214 
haplotype. 215 
 216 
Results 217 
 218 
Incidence of malaria recurrences by P. vivax and risk factors  219 
Of 134 participants screened, 87 met the inclusion criteria (Figure 2). Participants included 220 
and excluded were similar in demographic characteristics and history of malaria (Table S1). 221 
All participants included in the recurrence surveillance had a negative malaria PCR result on 222 
day 28 post initial treatment. During the six month follow-up, 29 recurrences in 21 223 
participants were detected. Seven participants had two recurrences while one had three 224 
recurrences. The remaining 66 participants (75.9%) did not develop recurrent malaria during 225 
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the study period (censored cases), although seven of them were lost to follow-up within the 226 
six month period. 227 
 228 
The average follow-up time was 170.34 days with a standard deviation (SD) of 3.06 days; 229 
cumulative incidence to first recurrence was 24.1% at 180 days post treatment (95% CI 14.6 230 
- 33.7); 86% (18/21) of the participants had their first recurrence between 51 and 110 days 231 
after enrolling in the study (Figure 3). Seven participants had a second recurrence event 232 
between days 118 and 177 and one presented a third recurrence on day 179. 233 
 234 
Characteristics of participants with and without recurrence are presented on Table 1, while 235 
crude and adjusted HR are shown on Table 2. After adjusting for history of malaria in the 236 
preceding year, time of residence in an endemic area for longer than 5 years was the only 237 
factor associated with malaria recurrence (HR = 2.5, 95% CI 1.04 to 4.87).  238 
 239 
Genetic diversity of P. vivax 240 
A total of 157 samples were genotyped: 128 Day Zero samples (participants included and 241 
excluded from monitoring of recurrences) and 29 recurrences. 87.5% of samples from Day 242 
Zero (n = 112) and 100% of the recurrences were monoclonal infections. All polyclonal 243 
infections had two clones. Two samples collected on Day Zero (1.4%) did not amplify an 244 
allele at one MS locus (MS20 and MS12.335) while all seven loci were successfully 245 
amplified in all recurrence samples. 246 
 247 
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Average He was 0.721 ± 0.036 in samples from Day Zero. The average number of alleles per 248 
locus was 8.71 ± 3.2 and average alleles/locus per sample was 1.04. MS20 was the most 249 
polymorphic locus with He = 0.860, and it discriminated 43.7% of polyclonal infections. 250 
(Table 3). A total of 52 MLH were detected in 112 monoclonal samples from Day Zero, of 251 
which 34 (65.4%) were only present in a single sample (Figure 4). H33 and H3 MLH were 252 
the most frequently detected from the Day Zero group, in 21.4% (24/112) and 9.8% (11/112) 253 
of the samples, respectively.  254 
 255 
Average He was 0.664 ± 0.050 in the 29 recurrence samples. Among them 13 MLH were 256 
identified, of which H33 had a frequency of 24.1% and H16 of 20.7%; H54 and H55 were 257 
new haplotypes not identified in samples from Day Zero and H53 was identified only in a 258 
polyclonal sample from Day Zero. 259 
 260 
In Figure 4, the monthly distribution of haplotypes detected during the study period is 261 
presented. Two genetic clusters were inferred using Structure program, including the data 262 
from monoclonal infections (Fig S1), and all samples had a greater than 75% probability of 263 
belonging to one of the two possible genetic clusters. A total of 87 isolates (60.4%) with 46 264 
haplotypes belonged to cluster 1; while 57 isolates (39.6%) with nine haplotypes belonged 265 
to cluster 2. The samples were classified into these groups to estimate haplotype frequencies 266 
on Day Zero and P(match). Both clusters of P. vivax circulated simultaneously in Turbo 267 
during the study period but their geographic distribution was slightly different (Fig S2). 268 
These clusters, however, could be genetically interrelated as indicated by the haplotype 269 
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network (Fig S3) with the putative primary founders in the less diverse cluster 2. Importantly, 270 
all MLH lineages were found in all localities so this source of bias did not affect our results. 271 
 272 
 273 
Classification of recurrences by P. vivax 274 
MLH from participants with recurrences are presented in Table 4. Of a total of 29 275 
recurrences, 27 were identical haplotypes to those present on Day Zero (Table 4 and Table 276 
S2) to the results from the P(match) analysis for classification of recurrences indicated that  277 
65.5% (19/29)  were relapses from initial infection.  278 
 279 
Cluster 1 contained 12 participants with recurrences and a total of 18 recurrence events 280 
(Table 4). The recurrences in two participants from this group were classified as reinfections 281 
(i.e. new infection) because the MLH from Day Zero and day of recurrence were not 282 
identical. Nevertheless, the recurrence haplotypes were highly genetically related to the 283 
infection episode at the time of inclusion in the study with differences at only two alleles 284 
(Table S2).  285 
 286 
A group of nine participants were assigned to cluster 2 with a total of 11 recurrence events, 287 
all of which were caused by haplotypes that were identical to the previous episode/s (Table 288 
4). There were six recurrences by the predominant haplotype (H33), which had a very high 289 
P(match), thus making it highly likely that participants were reinfected with the same parasite 290 
strain that was detected on Day Zero. 291 
 292 
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Discussion 293 
 294 
In this study we found that 24.1% (21/87) of P. vivax-infected participants had at least one 295 
recurrence within 180 days of treatment with a standard CQ-PQ regimen, despite receiving 296 
full treatment and being monitored. Additionally, 8% (7/87) of participants had three or more 297 
episodes within six months. Moreover, it is highly unlikely that these recurrences were 298 
recrudescence by therapeutic failure to CQ, since all participants had a negative PCR for 299 
malaria on day 28 post-treatment. Results from similar studies in other parts of the world 300 
reported a cumulative incidence of recurrence between 0% and 13.5% after treatment with 301 
0.25 mg/kg/day PQ for 14 days and follow-up time between 180 and 210 days, which is much 302 
lower than what was found in this study (38-43). 303 
 304 
A similar study carried out in two endemic regions of Colombia (2003 – 2004), reported 305 
cumulative incidence of 16.2% for a first recurrence of P. vivax during six months after 306 
treatment with the same regimen as in the present study and only 1.5% of the participants 307 
had more than one recurrence event (14). Although the difference in cumulative incidence of 308 
recurrence is seemingly little between these two studies, recurrences in the previous study 309 
are more likely to have been cases of reinfection, rather than relapses, since API in that study 310 
was much higher than the present one (30 vs 3) (15, 44). In addition, a maximum PQ dose of 311 
210 mg was used in the previous study, so participants weighing more than 60 kg body weight 312 
received a lower dose than recommended; in the present study, all participants were dosed 313 
by body weight to avoid relapse due to under-dosing, as previously reported in other studies 314 
(26, 45, 46).  315 
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 316 
P. vivax recurrences may have an impact on patient wellbeing via clinical symptoms and the 317 
risk of complicated malaria. In this study, participants presented clinical symptoms in all 318 
episodes of malaria, although recurrent episodes were not always febrile. Moreover, P. vivax 319 
gametocytes were present at recurrence, which may have contributed to ongoing transmission 320 
(4). 321 
 322 
Potential risk factors for P. vivax recurrence were explored. Duration of residence of more 323 
than 5 years in this endemic area was associated with an increased risk of recurrence, even 324 
after adjusting for malaria history in the last year. Although this result seems to contradict 325 
previous reports (25), our interpretation is that a longer time of exposure to malaria, and 326 
therefore a greater probability of having had previous episodes, may increase the likelihood 327 
of hosting dormant hypnozoites. Importantly, in this study a sample size was not considered 328 
to assess risk factors associated with recurrence; which limited precision in estimates of risk 329 
factors for recurrence. 330 
 331 
This study included the 74% of P. vivax malaria reported cases in four diagnostic centers 332 
from Turbo municipality during the study period, so the parasite sample genotyped (n=157) 333 
can be considered a reliable representation of the P. vivax strains responsible for symptomatic 334 
infections in the study area. The detection of 52 haplotypes in 112 Day Zero samples, and 335 
the high percentage of unique haplotypes (65.4%) shows high genetic diversity, consistent 336 
with other reports from South America using P. vivax microsatellites (37, 47-50). Overall, 337 
the percentage of samples with polyclonal infection was 12.5%, which is similar to reports 338 
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from other populations in Colombia, Venezuela and Peru (47, 50, 51). The genetic diversity 339 
of the selected markers indicates that they have enough resolution to detect differences 340 
among samples of P. vivax in Turbo. 341 
 342 
About 93.1% of recurrences analyzed were caused by MLH that were identical to those of 343 
the first episode (Day Zero sample). This percentage is higher than reported in other studies 344 
that used the same PQ supervised regimen, similar length of follow-up and genotyping 345 
approach of recurrences (microsatellite loci) (37, 40). Additionally, 62.1% of recurrences 346 
were classified as relapses according to established criteria based on estimation of P(match) 347 
within each genetic cluster, which could indicate a problem with efficacy of the PQ regimen 348 
used. The criteria used in this study for classification of recurrences were strict, and 349 
additional information collected during follow-up — such as travel to other endemic areas, 350 
family members with malaria in the same household, and use of preventive measures for 351 
malaria — supported this interpretation. 352 
 353 
Several aspects of this study support the finding that at least six out of ten P. vivax recurrences 354 
in Turbo, Colombia, are caused by relapses: A PQ regimen with low incidence of recurrences 355 
reported worldwide was used. CQ-PQ treatment was supervised to completion. PQ daily dose 356 
was adjusted for body weight, even in patients over 60 kg. No recrudescence was confirmed 357 
by negative P. vivax PCR on day 28. Remarkably, most recurrences were caused by 358 
genetically identical parasites to the previous episode. Given the high genetic diversity of P. 359 
vivax in the study area, the probability of reinfection with an identical MLH in this area is 360 
extremely low. Most recurrences occurred between 51 and 110 days of a previous episode, 361 
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which agrees with previously reported timing for P. vivax relapses from South America, 362 
characterized by short latency time (3). API was low during the study period and therefore 363 
the probability of reinfection was also low. Most participants with recurrences had not visited 364 
another endemic area during follow-up, and they had not family members infected with 365 
malaria. There were recurrences in participants who resided in urban areas where currently 366 
there is no malaria transmission and therefore it was not possible for the participants to 367 
acquire a new infection. 368 
 369 
The high incidence of relapses found in this study was possibly caused by the current standard 370 
dose of PQ used in Colombia being insufficient to eliminate hypnozoites. It was recently 371 
reported that PQ metabolism by the cytochrome P450 2D family of enzymes is required for 372 
antimalarial activity in humans and lower CYP 2D6 enzyme activity, as in the poor-373 
metabolizer phenotype, could compromise its radical curative efficacy (52). It is not clear if 374 
any such variation in the genetic background of this population could account for this 375 
observation. In addition, it has been shown that when using higher doses of PQ such as 0.5 376 
mg/Kg for 14 days as  recommended by the CDC (53), lower incidence of recurrences are 377 
reported (between 1.9% and 6.6% during 180 - 365 days) (43, 54, 55). However, no direct 378 
comparison had been made of PQ regimen 0.5 mg/Kg for 14 days with the standard regimen 379 
in malaria endemic countries (9). Further studies addressing this subject and evaluating the 380 
optimal dose and type of treatment are required, as well as to establish a minimum effective 381 
concentration of PQ in order to define therapeutic failure.  382 
 383 
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For elimination of malaria by P. vivax, surveillance of recurrences is necessary, including 384 
genotyping and monitoring of different factors associated with it. This type of approach not 385 
only allows for the classification of recurrence as reinfection or relapse, but opens the 386 
prospect of identifying PQ tolerance markers, evaluating the efficacy and safety of 387 
therapeutic PQ regimens with optimal doses for different epidemiological contexts, and 388 
advancing the search for new agents against liver hypnozoites. 389 
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Figures legends 590 
 591 
Figure 1. Map of study area. Participants were recruited in hospital of Turbo located in urban 592 
center and three health centers in the periphery (El Dos, Tres and Currulao). 593 
 594 
Figure 2. Flowchart of enrolled participants, under supervised treatment with chloroquine 595 
and primaquine. 596 
 597 
Figure 3. Survival curve Kaplan-Meier for participants included in monitoring of malaria 598 
recurrences by Plasmodium vivax. 599 
 600 
Figure 4. Monthly distribution of multilocus haplotypes of Plasmodium vivax in Turbo-601 
Colombia identified during the study period. Vertical axis are number of cases and horizontal 602 
axis are dates (year - month). Monthly frequency of haplotypes in monoclonal samples from 603 
Day Zero (n=115) (a) and recurrence day (n=29) (b), each color represents a different 604 
haplotype.  605 
  606 
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Tables 607 
 608 
Table 1. Characteristics of participants enrolled for monitoring of malaria recurrences by 609 
Plasmodium vivax. 610 
 
RECURRENCE  
(n=21) 
NO RECURRENCE 
(n=66) 
P valuea 
Sex male; n (%) 14 (66.7) 37 (56.1) 0.209 
Age, years; median (IQR) 25 (17.0 – 35.5) 29 (15.7 – 45.2) 0.258 
Body mass index, kg/m2; median (IQR)  23.0 (20.2 – 26.2) 22.7 (20.0 – 24.8) 0.659 
Occupation; n (%)    
Farmer 8 (38.1) 19 (29.7) 
0.616 
Housewife 5 (23.8) 16 (25.0) 
Student 5 (23.8) 18 (28.1) 
Other job 3 (14.3) 11 (17.2) 
Likely source of infection within Turbo; n (%) 17 (80.9) 60 (90.9) 0.182 
Rural residence; n (%) 14 (66.7) 41 (62.1) 0.486 
Parasitemia Day Zero, parasites/µL; median (IQR) 4,480 (2280 – 7080) 4,940 (2100 -9590) 0.797 
Number of days with symptoms before diagnosis; median (IQR) 5 (4 – 6.5) 5 (3 – 7) 0.210 
Time of residence in endemic region, years; median (IQR) 12 (2.5 – 20) 4 (1 – 12) 0.043 
Symptomatic malaria in last year; n (%) 8 (38.1) 14 (21.1) 0.390 
Number of malaria episodes in last year; median (IQR) 1 (1 – 1.7) 1 (1- 2) 0.390 
Last episode of symptomatic malaria; n (%)    
1 to 2 months 5 (25.0) 3 (4.8) 
0.882 
3 to 6 months 2 (10.0) 10 (15.9) 
7 to 12 months 1 (5.0) 1 (1.6) 
> 12 months 5 (25.0) 25 (39.7) 
30 
 
No history of malaria 7 (35.0) 24 (38.1) 
CQ dosage, mg/kg; median (IQR) 24.2 (22.3 – 26.1) 23.9 (22.1 – 26.4) 0.387 
PQ dosage, mg/kg; median (IQR) 3.6 (3.4 – 4.1) 3.7 (3.5 – 4.1) 0.500 
Travel to other endemic region during follow-up; n (%) 7 (35.0) 19 (37.2) 0.954 
Using bed-net during follow-up; n (%)    
Always 12 (60.5) 33 (61.9) 
0.776 Never 5 (25.0) 9 (16.7) 
Some months 3 (15.0) 12 (22.2) 
Using insecticides to spray house during follow-up; n (%) 14 (70.0) 25 (48.1) 0.286 
 611 
IQR, interquartile range 612 
a
 Cox regression, Andersen-Gill extension 613 
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Table 2. Potential risk factors for Plasmodium vivax malaria recurrence during six month follow-up. 614 
 
Crude HRa  95% CI Adjusted HRb 95% CI 
Sex 
Female 
Male 
 
1 
1.66 
 
 
0.75 – 3.69  
 
 
1.59 
 
 
0.71 – 3.56 
Age 
< 18 years  
≥ 18 years  
 
1 
1.69 
 
 
0.73 – 3.94 
 
1 
1.52 
 
 
0.66 – 3.51 
Time of residence in endemic region  
≤ 5 years 
> 5 years 
 
1 
2.19 
 
 
1.00 – 4.77 
 
1 
2.25 
 
 
1.04 – 4.87 
Number of days with symptoms before diagnosis  
< 5 days 
≥ 5 days 
 
1 
0.79 
 
 
0.38 – 1.66 
 
1 
0.85 
 
 
0.40 – 1.80 
Parasitemia Day Zero 
< 4,920 parasites/µL 
≥ 4,920 parasites/µL 
 
1 
1.11 
 
 
0.50 – 2.44 
 
1 
1.19 
 
 
0.54 – 2.61 
Symptomatic malaria in last year  
No 
 
1 
 
 
 
1 
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Yes 1.41 0.65 – 3.07 1.50 0.70 – 3.25 
Place of residence  
Urban 
Rural 
 
1 
1.33 
 
 
0.60 – 2.93 
 
1 
1.39 
 
 
0.63 – 3.09 
Travel to other endemic region during follow-up  
No 
Yes 
 
1 
0.98 
 
 
0.45 – 2.11 
 
1 
1.02 
 
 
0.48 – 2.14 
Using bed-net during follow-up  
Always  
Never 
Some months 
 
1 
1.32 
0.75 
 
 
0.52 – 3.36 
0.26 – 2.17 
 
1 
1.11 
0.79 
 
 
0.41 – 3.00 
0.29 – 2.16 
Using insecticides to spray house during follow-up 
Yes 
No 
 
1 
0.64 
 
 
0.29 – 1.45 
 
1 
0.83 
 
 
0.34 – 2.03 
 615 
a Cox regression, Andersen-Gill extension  616 
b
 Cox regression, Andersen-Gill extension. Adjusted for symptomatic malaria in last year and time of residence in endemic region > 5 years.  617 
HZ, Hazard ratio. CI, confidence interval 618 
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Table 3. Genetic diversity of Plasmodium vivax per locus from Day Zero samples. 619 
LOCUS 
Total 
number of 
alleles* 
Allele size range  
(bp) 
Expected 
heterozygosity 
(He) a 
Polyclonal 
samples 
(%) 
Average  
alleles/locus/sample 
MS2 11 181 - 251 0.791 5.47 1.05 
MS6 6 211 - 249 0.746 3.13 1.03 
MS20 15 206  - 263 0.860 5.51 1.06 
2.21 7 83 - 115 0.644 3.91 1.04 
3.502 7 133 - 199 0.768 7.03 1.07 
11.162 8 181 - 243 0.643 2.34 1.02 
12.335 7 160 - 179 0.598 3.94 1.04 
 620 
a
 Only from monoclonal samples (n=112). He represents probability of finding two different 621 
alleles for a given locus on a pair of isolated randomly selected from the study population 622 
(He = n/(n-1)(1-∑pi 2), where p is i-th frequency allele and n is sample size. 623 
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Table 4. Multilocus haplotypes in 21 participants with recurrences by Plasmodium vivax during six months. 
 ID 
SAMPLE 
Time from 
Day Zero 
to first 
recurrence 
Time from 
Day Zero 
to second 
recurrence 
Comparison 
Day Zero vs 
recurrence 
day 
Haplotype code Cluster P(match)a Classificationb 
Residence 
zone 
Last episode of 
malaria before 
study 
Travel to 
other endemic 
region during 
follow-up 
Family 
member with 
malaria at 
time of 
recurrence 
1014 54  Identical 6 2 0.0019 Relapse Rural more 12 months No No 
1015 68 154 Identical 33c 2 0.5146 Reinfection Rural never No No 
1018 173  Identical 33 2 0.5146 Reinfection Rural 7-12 months No No 
1022 94  Identical 25 1 0.0008 Relapse Rural 3-6 months No No 
1034 103 170 Identical 39c 1 0.0019 Relapse Urban never Si No 
1050 180  Identical 33 2 0.5146 Reinfection Rural 1-2 months Si No 
1051 90  Identical 33 2 0.5146 Reinfection Rural never No No 
1052 81 154 Identical 48* 1 0.0019 Relapse Rural more 12 months Si No 
1055 110  Identical 25 1 0.0008 Relapse Urban more 12 months Si No 
1057 91  Identical 33 2 0.5146 Reinfection Rural never No No 
1063 108  Different 13 (Day Zero) - 54 (R1) 1  Reinfection Rural more 12 months No No 
1065 72 142 Identical 3c 2 0.0572 Reinfection Rural more 12 months No No 
1066 80  Identical 28 2 0.0075 Relapse Urban never Si No 
1075 179  Different 10 (Day Zero) - 55 (R1) 1  Reinfection Urban 1-2 months Si No 
1089 75 145 Identical 26c 1 0.0002 Relapse Urban 1-2 months No No 
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1094 69  Identical 33 2 0.5146 Reinfection Rural 3-6 months No No 
1098 76  Identical 53 1 0.0002 Relapse Rural 1-2 months No No 
1101d 58 118 Identical 16c 1 0.0034 Relapse Rural more 12 months No Yes 
1102 99  Identical 16 1 0.0034 Relapse Rural never No No 
1103 57 177 Identical 16c 1 0.0034 Relapse Rural never No Yes 
1111 51  Identical 17 1 0.0002 Relapse Urban 1-2 months No No 
 
a
 Probability of finding by chance an identical haplotype in different episodes for a participant. b Relapse when P (match) is less than 0.05 and reinfection when greater or equal to 
0.05. c Second recurrence with haplotype identical to previous two episodes in the study. d Third recurrence day 179 with haplotype 16, identical to previous three episodes in the 
study.  





TABLE S1 Characteristics of participants included and excluded for monitoring 
recurrences. 
 INCLUDED 
 (n=87) 
EXCLUDED 
 (n=47) 
Sex; n (%) 
Male 
Female 
 
51 (58.6) 
36 (41.4) 
 
23 (48.9) 
24 (51.1) 
Age in years (median and IQR) 29 (16 - 39) 21 (15 – 32) 
Body weight (median and IQR) 60 (50 - 67) 58 (45 – 69) 
Occupation; n (%) 
Farmer 
Housewife 
Student 
Other job 
 
27 (31.8) 
21 (24.7) 
23 (27.1) 
14 (16.5) 
 
10 (21.7) 
14 (30.4) 
10 (21.7) 
12 (26.1) 
Likely place of infection; n (%) 
Turbo 
Outside Turbo 
 
77 (88.5) 
10 (115) 
 
36 (76.6) 
11 (23.4) 
Parasitemia Day Zero, parasites/L; median 
(IQR) 
4,920 (2,200 – 8,840) 4,960 (2,120 – 10,720) 
Number of days with symptoms before 
diagnosis; median (IQR) 
5 (4 – 7) 5 (4 – 8) 
Place of residence; n (%) 
Rural 
Urban 
 
55 (63.2) 
32 (36.8) 
 
32 (68.1) 
15 (31.9) 
Time of residence in endemic region; median 
(IQR)  
5.0 (1.0 – 15.0) 5.0 (1.0 – 15.7) 
Symptomatic malaria in last year; n (%) 
Yes 
No 
 
22 (25.3) 
65 (74.7) 
 
17 (37.0) 
29 (63.0) 
Number of malaria episodes in last year; 
median (IQR) 
1 (1 – 2) 1 (1 – 2) 
Last episode of symptomatic malaria; n (%) 
1 to 2 months 
3 to 6 months 
7 to 12 months 
> 12 months 
No history of malaria 
 
8 (9.6) 
12 (14.5) 
2 (2.41) 
30 (36.4) 
31 (37.5) 
 
5 (13.5) 
9 (24.3) 
1 (2.7) 
11 (29.7) 
11 (29.7) 
Health system affiliation regime; n (%) 
Contributory 
Subsidized 
Unaffiliated 
 
3 (3.7) 
74 (91.4) 
4 (4.9) 
 
1 (2.2) 
40 (88.9) 
4 (8.9) 
 
IQR, interquartile range 
  
TABLE S2 Multilocus haplotypes from participants with malaria recurrences by 
Plasmodium vivax during six months. 
 
Code 
sample 
Date sample 
collection 
Follow-
up day 
MS2 MS6 MS20 MS2.21 MS3.502 MS11.162 MS12.335 
1014 
14/02/2012 0 181 249 209 105 159 181 165 
09/04/2012 54 (R1) 181 249 209 105 159 181 165 
          
1015 
21/02/2012 0 214 249 215 105 167 181 162 
28/04/2012 68 (R1) 214 249 215 105 167 181 162 
23/07/2012 154 (R2) 214 249 215 105 167 181 162 
          
1018 
03/03/2012 0 214 249 215 105 167 181 162 
23/08/2012 173 (R1) 214 249 215 105 167 181 162 
          
1022 
26/03/2012 0 206 249 221 105 142 181 179 
29/06/2012 94 (R1) 206 249 221 105 142 181 179 
          
1034 
13/04/2012 0 214-239 239-249 209-224 83-105 142-151 181-185 162-165 
25/07/2012 103 (R1) 214 249 224 83 151 185 162 
30/09/2012 170 (R2) 214 249 224 83 151 185 162 
          
1050 
22/06/2012 0 214 249 215 105 167 181 162 
10/01/2013 180 (R1) 214 249 215 105 167 181 162 
          
1051 
25/06/2012 0 214 249 215 105 167 181 162 
25/09/2012 90 (R1) 214 249 215 105 167 181 162 
          
1052 
26/06/2012 0 239 246 209 105 151 181 165 
15/09/2012 81 (R1) 239 246 209 105 151 181 165 
27/11/2012 154 (R2) 239 246 209 105 151 181 165 
          
1055 
14/07/2012 0 206 249 221 105 142 181 179 
01/11/2012 110 (R1) 206 249 221 105 142 181 179 
          
1057 
14/07/2012 0 214 249 215 105 167 181 162 
13/10/2012 91 (R1) 214 249 215 105 167 181 162 
          
1063 
03/10/2012 0 189 243 212 103 167 197 162 
18/01/2013 108 (R1) 189 243 212 103 167 201 162 
          
1065 
17/10/2012 0 181 227 209 105 159 201 162 
28/12/2012 72 (R1) 181 227 209 105 159 201 162 
08/03/2013 142 (R2) 181 227 209 105 159 201 162 
          
1066 
17/10/2012 0 214 227 218 107 167 201 162 
05/01/2013 80 (R1) 214 227 218 107 167 201 162 
          
1075 
31/10/2012 0 189 239 236 105 151 201 165 
28/04/2013 179 (R1) 218 239 236 105 151 201 162 
          
1089 
16/02/2013 0 209 211 209 107 133 193 171 
02/05/2013 75 (R1) 209 211 209 107 133 193 171 
11/07/2013 145 (R2) 209 211 209 107 133 193 171 
          
1094 
13/04/2013 0 214 249 215 105 167 181 162 
21/06/2013 69 (R1) 214 249 215 105 167 181 162 
          
1098 
06/05/2013 0 206 211 206-240 107 167 181 162 
21/07/2013 76 (R1) 206 211 206 107 167 181 162 
          
1101 
28/05/2013 0 206 211 240 107 167 181 162 
25/07/2013 58 (R1) 206 211 240 107 167 181 162 
23/09/2013 118 (R2) 206 211 240 107 167 181 162 
23/11/2013 179 (R3) 206 211 240 107 167 181 162 
          
1102 
29/05/2013 0 206 211 206-240 107 167 181 162 
05/09/2013 99 (R1) 206 211 240 107 167 181 162 
          
1103 
29/05/2013 0 206 211 240 107 167 181 162 
25/07/2013 57 (R1) 206 211 240 107 167 181 162 
22/11/2013 177 (R2) 206 211 240 107 167 181 162 
          
1111 
08/07/2013 0 206 239 212 97 159 201 160 
28/08/2013 51 (R1) 206 239 212 97 159 201 160 
 
R1, first recurrence 
R2, second recurrence 
R3, third recurrence 
 
 
 
 
 
 
  
  
a) 
 
 
 
 
 
 
 
b) 
 
FIG S1 Population structure analysis of Plasmodium vivax monoclonal samples from Day 
Zero and recurrence day using Structure 2.3.4 program. a) Probability of assignment of all 
samples to each of K populations previously established. b) Bar graph for K = 2, each sample 
is represented by a vertical bar divided into K colors. Each color represents a cluster and 
segment size shows probability of a sample of belonging to certain cluster, 87 isolates belong 
to cluster 1 (red) and 57 to cluster 2 (green). 
  
  
FIG S2 Geographical distribution of the two genetic clusters obtained by Bayesian analysis. 
The geographical location reflects the participants residence place. Each sample corresponds 
to individual multilocus haplotype, which are monoclonal infections of P. vivax detected at 
day Zero and recurrence day. Each color represents a genetic cluster (n = 144). 
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FIG S3 Minimum spanning tree for Plasmodium vivax constructed using goeBURST algorithm. The tree depicts the relationships 
among multilocus haplotypes (MLH) at the n locus variants level of Plasmodium vivax monoclonal samples from Day Zero and 
recurrence day (where n equals to the number of loci in our dataset: seven). Each MLH is represented by a circle with size being 
proportional to its frequency and the links are character differences. The color of each circle represents the cluster identified by 
Structure v2.3.4 (panel left) and study localities (panel right). 
 
